Profile data is unavailable for this security.
About the company
Fagron NV, formerly Arseus NV, is a Belgium-based company that is active in the healthcare sector. It operates as a research and development (R&D) scientific pharmaceutical compounding supplier and operates through four segments: The Fagron Specialty Pharma Services segment comprises personalized medication that is produced in the Company's compounding facilities; the Fagron Trademarks segment encompasses concepts and formulations developed by the Company's research and development (R&D) team; Fagron Essentials comprises pharmaceutical raw materials, equipment and supplies for pharmacies, and the HL Technology segment includes the development and production of precision components and orthopedic tools for dental and medical professionals.
- Revenue in EUR (TTM)496.16m
- Net income in EUR50.81m
- Incorporated2007
- Employees2.49k
- LocationFagron NVVenecoweg 20ANAZARETH 9810BelgiumBEL
- Phone+32 80012880
- Fax+32 92162491
- Websitehttps://fagron.com/
More ▼
Mergers & acquisitions
| Acquired company | FAGR:BRU since announced | Transaction value |
|---|---|---|
| Central De Drogas SA De CV | -4.86% | 24.22m |
| Dr. Kulich Pharma sro | -4.86% | 6.18m |
Data delayed at least 15 minutes, as of Sep 13 2019 16:35 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avon Rubber plc | 182.19m | 15.92m | 587.62m | 784.00 | 36.62 | 7.26 | 20.26 | 3.23 | 0.4583 | 0.4583 | 5.25 | 2.31 | 1.03 | 4.14 | 8.65 | 205,867.30 | 8.99 | 14.95 | 11.76 | 20.77 | 39.41 | 36.76 | 8.74 | 11.86 | 1.79 | -- | 0.0014 | 17.93 | 3.96 | 5.80 | -9.17 | 17.51 | -4.24 | 29.97 |
| Biotage AB | 93.68m | 16.26m | 636.58m | 438.00 | 39.01 | 8.66 | 29.66 | 6.80 | 2.66 | 2.66 | 15.35 | 11.99 | 0.909 | 2.84 | 4.46 | 2,461,469.00 | 15.78 | 15.12 | 18.83 | 18.34 | 61.62 | 58.60 | 17.36 | 15.67 | 1.82 | 213.01 | 0.2093 | 74.25 | 21.75 | 15.42 | 20.81 | 32.28 | 2.67 | 20.11 |
| CellaVision AB | 36.75m | 9.12m | 690.31m | 124.00 | 75.73 | 23.28 | 69.90 | 18.78 | 4.07 | 4.07 | 16.40 | 13.23 | 1.07 | 3.64 | 7.43 | 3,342,667.00 | 26.54 | 24.00 | 31.68 | 30.00 | 74.19 | 71.83 | 24.80 | 21.68 | 4.04 | 2,022.39 | 0.0871 | 55.20 | 17.94 | 15.19 | 27.20 | 36.19 | 14.19 | 24.57 |
| Stratec SE | 209.26m | 13.78m | 814.70m | 1.22k | 59.16 | 5.48 | 23.47 | 3.89 | 1.15 | 0.8302 | 17.41 | 12.37 | 0.7574 | 3.04 | 5.54 | 170,405.50 | 4.99 | 9.76 | 5.93 | 11.90 | 25.85 | 32.13 | 6.59 | 11.36 | 1.53 | 18.20 | 0.3904 | 46.04 | -9.47 | 7.98 | -58.22 | -6.42 | 14.01 | 6.45 |
| Arjo AB (publ) | 808.87m | 33.26m | 909.90m | 6.18k | 29.31 | 1.81 | 7.97 | 1.12 | 1.30 | 1.30 | 31.60 | 21.01 | 0.6278 | 3.83 | 5.03 | 1,396,269.00 | 2.58 | -- | 3.80 | -- | 44.32 | -- | 4.11 | -- | 0.6983 | 5.22 | 0.357 | -- | 6.88 | -- | 150.85 | -- | -- | -- |
| Paul Hartmann AG | 2.16bn | 73.68m | 1.04bn | 11.11k | 14.07 | 1.15 | 6.40 | 0.4836 | 20.75 | 20.75 | 607.41 | 253.16 | 1.41 | 2.57 | 5.41 | 195,635.70 | 5.14 | 6.50 | 7.00 | 8.81 | 57.01 | 56.90 | 3.64 | 4.32 | 1.23 | 31.39 | 0.107 | 30.05 | 2.94 | 3.38 | -10.51 | 6.60 | 4.24 | 4.19 |
| Fagron NV | 496.16m | 50.81m | 1.17bn | 2.49k | 22.86 | 5.45 | 15.56 | 2.35 | 0.7108 | 0.5096 | 6.94 | 2.98 | 0.6865 | 3.53 | 11.07 | 199,419.20 | 7.10 | 2.34 | 9.83 | 4.15 | 44.94 | 44.78 | 10.34 | 4.11 | 0.7789 | 5.23 | 0.6302 | 38.41 | 8.80 | 6.60 | -8.13 | 0.5266 | -0.1623 | -30.06 |
| Ypsomed Holding AG | 413.69m | 54.82m | 1.49bn | 1.60k | 27.16 | 4.31 | 15.61 | 3.61 | 4.77 | 4.77 | 36.00 | 30.06 | 0.8341 | 5.32 | 4.82 | 282,895.90 | 11.05 | 9.97 | 15.87 | 13.82 | 34.47 | 31.27 | 13.25 | 10.94 | 0.6726 | 37.85 | 0.2436 | 28.63 | -2.65 | 10.43 | 15.51 | 34.61 | 33.32 | 12.89 |
| Medacta Group SA | 290.86m | 32.83m | 1.54bn | 1.04k | 34.22 | 14.64 | 25.09 | 5.30 | 2.47 | 2.47 | 19.48 | 5.78 | -- | -- | -- | 327,893.60 | -- | -- | -- | -- | 74.19 | -- | 11.29 | -- | 0.6559 | 6.75 | 0.6137 | -- | 11.41 | -- | 19.16 | -- | -- | -- |
Data as of Sep 13 2019. Currency figures normalised to Fagron NV's reporting currency: Euro EUR
14.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Evermore Global Advisors LLCas of 12 Apr 2019 | 2.20m | 3.07% |
| JPMorgan Asset Management (UK) Ltd.as of 11 Apr 2019 | 1.96m | 2.73% |
| Carmignac Gestion SAas of 12 Apr 2019 | 1.49m | 2.08% |
| The Vanguard Group, Inc.as of 31 Jul 2019 | 1.04m | 1.44% |
| Teslin Capital Management BVas of 30 Sep 2018 | 884.06k | 1.23% |
| Henderson Global Investors Ltd.as of 31 Jul 2019 | 672.87k | 0.94% |
| KBC Asset Management NVas of 31 Dec 2018 | 636.32k | 0.89% |
| S.W. Mitchell Capital LLPas of 31 Mar 2019 | 631.82k | 0.88% |
| BlackRock Fund Advisorsas of 05 Sep 2019 | 607.43k | 0.85% |
| BNP Paribas Asset Management Belgium SAas of 30 Aug 2019 | 583.29k | 0.81% |
More ▼
Data from 31 Dec 2018 - 30 Aug 2019Source: FactSet Research Systems Inc.
